| 37.98 Data as of May 20 |  -0.55 / -1.43%Today’s Change | 31.28 Today|||52-Week Range 39.09 | +7.53% Year-to-Date |
| July Options Now Available For Forest Laboratories (FRX) May 20 / TheStreet.com | Forest-Trevena Ink Deal - Analyst Blog May 14 / Zacks.com |
| Forest Reaches New 52-Week High (FRX) May 14 / TheStreet.com | Positive Data on Forest Combo Drug - Analyst Blog May 07 / Zacks.com |
| Previous close | 38.53 |
| Today’s open | 38.53 |
| Day’s range | -- - -- |
| Volume | 792,688 |
| Average volume (3 months) | 1,338,098 |
| Market cap | $10.3B |
| Dividend yield | -- |
| Earnings growth (last year) | -0.56% |
| Earnings growth (this year) | -88.97% |
| Earnings growth (next 5 years) | +37.00% |
| Revenue growth (last year) | +4.26% |
| P/E ratio | NM |
| Price/Sales | 2.16 |
| Price/Book | 1.80 |
| Today’s change | Today’s % change | |
|---|---|---|
| PRGOPerrigo Co | -0.45 | -0.38% |
| BMRNBioMarin Pharmaceuti... | -1.58 | -2.47% |
| MYLMylan Inc | -0.12 | -0.38% |
| ONXXOnyx Pharmaceuticals... | -1.31 | -1.37% |
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | $0.10 |
| Annual revenue (last year) | $4.4B |
| Annual profit (last year) | $979.1M |
| Net profit margin | 22.29% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman, President & Chief Executive Officer Howard Solomon |
Senior Vice President & Operations Director Kevin Walsh |
Corporate headquarters New York, New York |
.
